Clinical characteristics and outcome of childhood de novo acute myeloid leukemia in Saudi Arabia: A multicenter SAPHOS leukemia group study

被引:14
|
作者
Jastaniah, Wasil [1 ,2 ]
Al Ghemlas, Ibrahim [3 ,4 ]
Al Daama, Saad [5 ]
Ballourah, Walid [6 ]
Bayoumy, Mohammad [7 ]
Al-Anzi, Faisal [8 ]
Al Shareef, Omar [9 ]
Alsultan, Abdulrahman [10 ]
Abrar, Mohammed Burhan [2 ]
Al Sudairy, Reem [11 ]
机构
[1] Umm AlQura Univ, Fac Med, Dept Pediat, Mecca, Saudi Arabia
[2] King Abdul Aziz Med City, Princess Noorah Oncol Ctr, Jeddah, Saudi Arabia
[3] King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia
[4] Alfaisal Univ, Fac Med, Riyadh, Saudi Arabia
[5] King Fahad Specialist Hosp, Dammam, Saudi Arabia
[6] King Fahad Med City, Riyadh, Saudi Arabia
[7] King Faisal Specialist Hosp & Res Ctr, Jeddah, Saudi Arabia
[8] Prince Faisal Bin Bandar Canc Ctr, Qaseem, Saudi Arabia
[9] Prince Sultan Mil Med City, Riyadh, Saudi Arabia
[10] King Saud Univ, Coll Med, Dept Pediat, Riyadh, Saudi Arabia
[11] King Abdul Aziz Med City, King Abdullah Specialized Childrens Hosp, Dept Pediat Hematol Oncol, Riyadh, Saudi Arabia
关键词
AML; Acute leukemia; Ethnic; Response; Risk; Developing; CHILDRENS-ONCOLOGY-GROUP; BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; PEDIATRIC AML; CURRENT CONTROVERSIES; SUPPORTIVE CARE; CANCER-GROUP; TRIAL; RISK; ADOLESCENTS;
D O I
10.1016/j.leukres.2016.08.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Geographic variation and ethnicity have been implicated to influence the outcome of pediatric acute myeloid leukemia (AML). Furthermore, survival outcomes from developing countries are reported to be inferior to developed nations. We hypothesized that risk-and response-based outcome in high-income resource-rich developing countries would be comparable to developed nations as access to care and supportive measures would be similar. A total of 193 children diagnosed with de novo AML between January 2005 and December 2012 were identified, of those 175 were evaluable for outcome. Patients were stratified into low-risk (LR), intermediate-risk (IR), or high-risk (HR) groups. The complete remission (CR), early death, and induction failure rates were: 85.7%, 2.3%, and 12%; respectively. The 5-year cumulative incidences of relapse (CIR) and non-relapse mortality (NRM) were 43.1% and 9.8% respectively; overall survival (OS) was 58.8 +/- 4% and event-free survival (EFS) 40.9 +/- 4.1%. The 5-year OS for LR, IR, and HR groups were 72.0 +/- 6.9%, 59.8 +/- 6.2%, and 45.1 +/- 7.4%; respectively (p = 0.003); and EFS 50.5 +/- 8.0%, 46.3 +/- 6.4%, and 23.3 +/- 6.4%; respectively (p = 0.001). This study demonstrated comparable outcomes to those reported from developed countries. This suggests that utilization of risk-and response based protocols in developing countries can overcome ethnic and geographic variation, if access to care and supportive measures were similar. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:66 / 72
页数:7
相关论文
共 50 条
  • [21] OUTCOME OF CHILDHOOD ACUTE MYELOID LEUKEMIA IN MALAYSIA
    Teh, K. H.
    Rahman, E. J. Abdul
    Menon, B.
    Ibrahim, H. Mohd
    Mohamed, M.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S327 - S327
  • [22] ACUTE MYELOID-LEUKEMIA IN ADULTS IN SAUDI-ARABIA
    SPENCE, DG
    PADMOS, MA
    CLINK, HM
    DEVOL, E
    SHETH, K
    ROBERTS, G
    BRITISH JOURNAL OF HAEMATOLOGY, 1988, 69 (01) : 130 - 130
  • [23] RAS MUTATION IN CHILDHOOD ACUTE MYELOID LEUKEMIA DOES NOT INFLUENCE CLINICAL OUTCOME: A STUDY OF THE JAPANESE CHILDHOOD AML COOPERATIVE STUDY GROUP
    Sano, Hirozumi
    Shimada, Akira
    Murata, Chisato
    Park, Myoung-ja
    Sotomatsu, Manabu
    Taki, Tomohiko
    Tabuchi, Ken
    Tawa, Akio
    Horibe, Keizo
    Tsuchida, Masahiro
    Hanada, Ryoji
    Tsukimoto, Ichiro
    Hayashi, Yasuhide
    PEDIATRIC BLOOD & CANCER, 2011, 57 (05) : 767 - 767
  • [24] Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study
    Hoff, Fieke W.
    van Dijk, Anneke D.
    Qiu, Yihua
    Hu, Chenyue W.
    Ries, Rhonda E.
    Ligeralde, Andrew
    Jenkins, Gaye N.
    Gerbing, Robert B.
    Gamis, Alan S.
    Aplenc, Richard
    Kolb, E. Anders
    Alonzo, Todd A.
    Meshinchi, Soheil
    Qutub, Amina A.
    de Bont, Eveline S. J. M.
    Horton, Terzah M.
    Kornblau, Steven M.
    HAEMATOLOGICA, 2022, 107 (10) : 2329 - 2343
  • [25] MOLECULAR MARKERS IN DE NOVO ACUTE MYELOID LEUKEMIA
    Salem, K.
    Alkhail, H. Aba
    HAEMATOLOGICA, 2014, 99 : 567 - 568
  • [26] De novo acute myeloid leukemia risk factors
    Strom, Sara S.
    Oum, Robert
    Gbito, Kplola Y. Elhor
    Garcia-Manero, Guillermo
    Yamamura, Yuko
    CANCER, 2012, 118 (18) : 4589 - 4596
  • [27] Frequent but nonrandom expression of lymphoid markers on de novo childhood acute myeloid leukemia
    Abdelhaleem, Mohamed
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2007, 83 (02) : 259 - 263
  • [28] Frequent but nonrandom expression of myeloid markers on de novo childhood acute lymphoblastic leukemia
    Abdelhaleem, Mohamed
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2007, 83 (01) : 138 - 141
  • [29] Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group
    Miyawaki, Shuichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (02) : 171 - 177
  • [30] Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia
    Wahlin, A
    Brinch, L
    Hornsten, P
    Evensen, SA
    Oberg, G
    Simonsson, B
    Hedenus, M
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1997, 58 (04) : 233 - 240